[Diffusion of piperacillin in the eye].
Intraocular diffusion of piperacillin was studied in 42 patients scheduled for cataract surgery (n = 35) or vitrectomy (n = 7). Piperacillin was administered intravenously (4 g/injection). Thirty-four patients were given a single dose and 8 were given two doses 12 hours apart. Peak piperacillin levels in the aqueous (7.3 mg/l) occurred one hour after the injection; levels in the vitreous were low (less than 0.6 mg/l). Intraocular diffusion of piperacillin was also studied in rabbits with an experimental Staphylococcus epidermidis infection of one eye; the other eye served as the control. In pigmented rabbits (6 Fauve de Bourgogne animals), increased diffusion and decreased elimination of piperacillin were seen in the aqueous, iris and cornea of the infected eyes, as compared with uninfected control eyes. In albino rabbits (6 New Zealand animals), results were less conclusive, with a difference between the infected and healthy eyes appearing only during the second hour following the injection. The good diffusion of piperacillin in the aqueous, especially in infected eyes (at least in rabbits), suggests that this drug may be useful for the treatment of ocular infections provided it is initiated early and given in combination with another antimicrobial exhibiting good intraocular diffusion.
Denis
F
F
Service de Bactériologie-Virologie, CHU Dupuytren, Limoges.
Mounier
M
M
Ploy
M C
MC
Adenis
J P
JP
Maes
S
S
D000368:Aged; D000818:Animals; D001082:Aqueous Humor / Q000187:drug effects / Q000378:metabolism / Q000382:microbiology; D002387:Cataract Extraction; D004058:Diffusion; D009877:Endophthalmitis / Q000517:prevention & control*; D005123:Eye / Q000187:drug effects / Q000378:metabolism* / Q000382:microbiology; D015818:Eye Infections, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D010878:Piperacillin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011300:Preoperative Care; D011817:Rabbits; D013212:Staphylococcus epidermidis / Q000302:isolation & purification*; D014821:Vitrectomy; D014822:Vitreous Body / Q000187:drug effects / Q000378:metabolism / Q000382:microbiology
D010878:Piperacillin
Diffusion de la pipéracilline dans l'ceil.